Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease
Not yet recruitingOBSERVATIONAL
Enrollment
90
Participants
Timeline
Start Date
April 26, 2024
Primary Completion Date
March 31, 2027
Study Completion Date
October 31, 2027
Conditions
Chronic Kidney Diseases
Interventions
OTHER
caspase 3 and ADAM 17 biomarkers
Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease
All Listed Sponsors
lead
Assiut University
OTHER
NCT06392425 - Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease | Biotech Hunter | Biotech Hunter